Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Blood (2020) 135 (15): 1255–1269.

https://doi.org/10.1182/blood.2019002922

Published: 2020

Includes: Supplemental data

Journal Articles

Overcoming Innate Resistance to a Beta-Catenin Inhibitor-BC2059- By Manipulating Autophagy in Multiple Myeloma

Ioanna Savvidou, MDPhD, Tiffany T. Khong, PhD, Stephen K. Horrigan, PhD, Andrew Spencer

Blood (2016) 128 (22): 5669.

https://doi.org/10.1182/blood.V128.22.5669.5669

Published: 2016

Journal Articles

In Vitro and In Vivo Efficacy of a Novel Orally Bioavailable Beta-Catenin Inhibitor-BC2059- As Monotherapy or in Combination with Proteasome Inhibitors in Multiple Myeloma

Ioanna Savvidou, MD PhDstudent, Tiffany T. Khong, PhD, Stephen K. Horrigan, PhD, Andrew Spencer

Blood (2015) 126 (23): 1816.

https://doi.org/10.1182/blood.V126.23.1816.1816

Published: 2015

Journal Articles

BC2059: An Orally Bioavailable β-Catenin Inhibitor Potently Induces Apoptosis As A Single Agent and In Combination With Bortezomib In Multiple Myeloma

Ioanna Savvidou, MD, Tiffany T. Khong, BSc, PhD, Stephen K. Horrigan, PhD, Andrew Spencer, MD

Blood (2013) 122 (21): 1920.

https://doi.org/10.1182/blood.V122.21.1920.1920

Published: 2013

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Kapil Bhalla, MD, Warren Fiskus, Ph.D., Stephen K. Horrigan, PhD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Sunil Sharma, MD

Blood (2012) 120 (21): 287.

https://doi.org/10.1182/blood.V120.21.287.287

Published: 2012

Journal Articles

Targeting the Wnt/Beta-Catenin Pathway in Multiple Myeloma with a Novel Orally Bioavailable Beta-Catenin Inhibitor

Ioanna Savvidou, MD, Tiffany T. Khong, BSc, PhD, Stephen K. Horrigan, PhD, Andrew Spencer, MD

Blood (2012) 120 (21): 1842.

https://doi.org/10.1182/blood.V120.21.1842.1842

Published: 2012

Journal Articles

Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells

Warren Fiskus, PhD, Jacqueline Smith, MS, Uma Mudunuru, MS, Stacey Hembruff, MS, Ruben Reyes, MD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Omar S. Aljitawi, MD, Siddhartha Ganguly, MD, Stephen K. Horrigan, PhD, Sunil Sharma, MD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 65.

https://doi.org/10.1182/blood.V118.21.65.65

Published: 2011

Journal Articles

In Vitro Characterization of Wnt/β-Catenin Pathway Inhibition in Multiple Myeloma Cell Lines Using a Novel Class of Small Molecules.

Jeffrey W. Strovel, PhD, Tammy Lawrence, B.S., Pachai Natarajan, M.S., Stephen Glanowski, Ph.D., Irina Lonskaya, Ph.D., Zoe Weaver, Ph.D., Janka Padia, Ph.D., Jeffrey W. Watthey, Ph.D., Wieslaw M. Cholody, Ph.D., J. Michael Hamilton, M.D., David K. Bol, Ph.D., Stephen K. Horrigan, Ph.D.

Blood (2007) 110 (11): 2523.

https://doi.org/10.1182/blood.V110.11.2523.2523

Published: 2007

Journal Articles

Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31

Stephen K. Horrigan, Zarema H. Arbieva, Hong Yan Xie, Jelena Kravarusic, Noreen C. Fulton, Haley Naik, Tiffany T. Le, Carol A. Westbrook

Blood (2000) 95 (7): 2372–2377.

https://doi.org/10.1182/blood.V95.7.2372

Published: 2000

Journal Articles

The Smad5 Gene Is Involved in the Intracellular Signaling Pathways That Mediate the Inhibitory Effects of Transforming Growth Factor-β on Human Hematopoiesis

Edward Bruno, Stephen K. Horrigan, David Van Den Berg, Elen Rozler, Priscilla R. Fitting, Steven T. Moss, Carol Westbrook, Ronald Hoffman

Blood (1998) 91 (6): 1917–1923.

https://doi.org/10.1182/blood.V91.6.1917

Published: 1998

NARROW

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Overcoming Innate Resistance to a Beta-Catenin Inhibitor-BC2059- By Manipulating Autophagy in Multiple Myeloma

In Vitro and In Vivo Efficacy of a Novel Orally Bioavailable Beta-Catenin Inhibitor-BC2059- As Monotherapy or in Combination with Proteasome Inhibitors in Multiple Myeloma

BC2059: An Orally Bioavailable β-Catenin Inhibitor Potently Induces Apoptosis As A Single Agent and In Combination With Bortezomib In Multiple Myeloma

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Targeting the Wnt/Beta-Catenin Pathway in Multiple Myeloma with a Novel Orally Bioavailable Beta-Catenin Inhibitor

Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells

In Vitro Characterization of Wnt/β-Catenin Pathway Inhibition in Multiple Myeloma Cell Lines Using a Novel Class of Small Molecules.

Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31

The Smad5 Gene Is Involved in the Intracellular Signaling Pathways That Mediate the Inhibitory Effects of Transforming Growth Factor-β on Human Hematopoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only